- Home
- JILL vs ANNX Comparison
JILL vs ANNX Comparison
Compare JILL & ANNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JILL
- ANNX
- Stock Information
- Founded
- JILL 1959
- ANNX 2011
- Country
- JILL United States
- ANNX United States
- Employees
- JILL N/A
- ANNX N/A
- Industry
- JILL Clothing/Shoe/Accessory Stores
- ANNX Biotechnology: Pharmaceutical Preparations
- Sector
- JILL Consumer Discretionary
- ANNX Health Care
- Exchange
- JILL Nasdaq
- ANNX Nasdaq
- Market Cap
- JILL 233.1M
- ANNX 252.3M
- IPO Year
- JILL 2017
- ANNX 2020
- Fundamental
- Price
- JILL $14.91
- ANNX $2.40
- Analyst Decision
- JILL Buy
- ANNX Strong Buy
- Analyst Count
- JILL 4
- ANNX 4
- Target Price
- JILL $29.75
- ANNX $12.50
- AVG Volume (30 Days)
- JILL 184.8K
- ANNX 1.3M
- Earning Date
- JILL 06-11-2025
- ANNX 08-11-2025
- Dividend Yield
- JILL 2.17%
- ANNX N/A
- EPS Growth
- JILL N/A
- ANNX N/A
- EPS
- JILL 2.24
- ANNX N/A
- Revenue
- JILL $602,968,000.00
- ANNX N/A
- Revenue This Year
- JILL $1.16
- ANNX N/A
- Revenue Next Year
- JILL $2.58
- ANNX N/A
- P/E Ratio
- JILL $6.57
- ANNX N/A
- Revenue Growth
- JILL N/A
- ANNX N/A
- 52 Week Low
- JILL $13.36
- ANNX $1.29
- 52 Week High
- JILL $40.00
- ANNX $7.85
- Technical
- Relative Strength Index (RSI)
- JILL 44.54
- ANNX 56.48
- Support Level
- JILL $13.53
- ANNX $2.32
- Resistance Level
- JILL $15.01
- ANNX $2.49
- Average True Range (ATR)
- JILL 0.76
- ANNX 0.18
- MACD
- JILL -0.02
- ANNX -0.03
- Stochastic Oscillator
- JILL 27.39
- ANNX 35.09
About JILL J. Jill Inc.
J.Jill Inc is a national lifestyle brand that provides apparel, footwear, and accessories. The company's products are marketed under the J.Jill brand name and sold through its two channels: its e-commerce platform and catalog (Direct) and its retail stores (Retail). Revenue is derived from the sale of apparel and accessory merchandise through the company's Retail and Direct channels, which include website and catalog phone orders. Revenue also includes shipping and handling fees collected from customers.
About ANNX Annexon Inc.
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.